Bristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
